IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
IGC Pharma, Inc. (IGC)
NASDAQ:AMEX Investor Relations:
igcinc.us/investor-center/overview
Company Research
Source: Business Wire
-- Study Deepens Understanding of Treatments for Alzheimer’s Patients, Enabling More Effective Treatments -- POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.The publication is titled “A study on CYP2C9 polymorphism in Puerto Rican Alzheimer's Patients and its role in the Pharmacokinetics of ?-9-tetrahydrocannabinol” and is available at https://esmed.org/MRA/mra/article/view/5380.The article highlights the importance of understanding genetic variations in CYP2C9, an enzyme crucial for drug metabolism, and its impact on the efficacy and safety of treatments involving THC. IGC Pharma’s leading drug candidate IGC-AD1 was tested in a Phase
Show less
Read more
Impact Snapshot
Event Time:
IGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGC alerts
High impacting IGC Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
IGC
News
- IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's DiseaseBusiness Wire
- IGC Reports Financial Results for Fiscal Year Ended March 31, 2024Business Wire
- IGC Pharma to Participate in Fireside Chat with Ascendiant Capital MarketsBusiness Wire
- Toronto's Anson Funds reaches settlement with U.S. regulator over short-selling practices [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Activist Hedge Fund Punished for Secret Payments to Researcher [Yahoo! Finance Canada]Yahoo! Finance Canada
IGC
Analyst Actions
- 6/21/24 - Ascendiant Capital
IGC
Sec Filings
- 6/24/24 - Form 10-K
- 5/21/24 - Form SC
- 5/13/24 - Form 4
- IGC's page on the SEC website